One likely reason the market has soured on Pro Medicus

Is there opportunity for brave investors?

| More on:
Two doctors give the thumbs up to an x-ray

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Ltd (ASX: PME) is once again trading lower, with its share price changing hands for $201.80 at market close on Friday. 

Having declined 23% since 3 March without any material announcements, investors may be left wondering what has transpired. 

Let's dig deeper.

Reality check: The valuation

Investors have likely come to terms with the fact that Pro Medicus is an expensive stock. 

Trading at a price-to-earnings (P/E) ratio of 215, it's hard to argue otherwise. It is expensive relative to not just the ASX wider market, which has traded at a historical average of 16, but also itself. Back in 2012, its P/E ratio sat at 20. Over the past 5 years, its median PE has expanded to 123.

What's it worth?

Given the range of outcomes, it's hard to determine what Pro Medicus is really worth. 

Pro Medicus certainly has a lot going for it and could grow into a much larger business. But the question is, how much bigger?

The company's flagship Visage 7 software is a market leader in terms of speed, functionality, and scalability. It boasts the fastest system and speed in the industry (ability to stream images). Visage 7 reportedly makes the diagnostic process 30% to 50% more efficient. It also improves accuracy, which is especially advantageous in the notoriously litigious U.S. It's easy to see why it has attracted a lot of support from industry professionals.  

Its track record speaks for itself, with the company consistently renewing existing contracts and winning new clients. It has been able to achieve this while increasing its price point. 

However, the stock is priced to perfection. Any slowdown in the volume of renewals would be likely to weigh on its valuation.

Similarly, if a valuable client were to decide not to renew, this would not be well received by the market.

With JP Morgan forecasting a 40% chance of a recession in the U.S. according to Reuters, its plausible some clients may not have the funds to renew. It may be beyond Pro Medicus' control and simply come down to budget cuts.

Several long-term tailwinds also strongly run its favour. These include an ageing population, the increased use of diagnostic imaging, cloud adoption, larger data sets, and remote access. This means that Pro Medicus is likely to continue to perform well in the long run, even if impacted in the short term. 

Pro Medicus also operates in a large addressable market of radiology in the U.S. Fortune Business Insights estimates the U.S. diagnostic imaging services market to grow from $130.38 billion in 2023 to $206.84 billion by 2030 at a compound annual growth rate (CAGR) of 6.8%. Last year, Pro Medicus estimated it had captured just 7% of this market, leaving plenty of upside potential. 

Is this a buying opportunity?

In a 'risk off' equities environment, it is usually the most expensive stocks that are punished the most. Between February 2024 and February 2025, Pro Medicus rocketed more than 200%. It's understandable that investors have taken some profits.

But, with the company approaching $200 for the first time since November 2024, there is an opportunity.

Those looking to add this high-performing ASX 200 healthcare stock to their portfolio appear to be in luck.

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »